Eli Lilly: Partnerships Better than Acquisitions
The Nikkei Asian Review website reported that Eli Lilly has drawn a line from expensive mergers and acquisitions, and intends to focus on partnerships for innovation; on open innovation. “Back in 1979, almost all our research took place within the company,” John Lechleiter, Eli Lilly CEO recalls. “Today, even though we spend almost $5 billion on R&D, we can only capture a tiny fraction of the research that is going on around the world. Open innovation is one tool that allows us to connect in a very unique way with a number of academic laboratories and small biotech companies.”
Click here to read the full article.